Moreover, the lorcaserin carcinogenicity studies were also thoroughly reviewed and discussed by the Center for DrugEvaluation and Research (CDER) Executive Carcinogenicity Assessment Committee, and the results of this scientific assessment were included in the background documents provided to the committee and discussed in Agency presentations at the Advisory Committee meeting.